Navigation Links
Eaton Apothecary Selects Predictive Acquisition Cost (PAC) Drug Price Type
Date:6/28/2012

TAMPA, Florida, June 28, 2012 /PRNewswire/ --


Holliston, Mass.-based pharmacy chain selects PAC from Elsevier / Gold Standard and Glass Box Analytics

Leading drug information provider, Elsevier / Gold Standard, announced today that Holliston, Mass.-based pharmacy chain Eaton Apothecary has purchased the new Predictive Acquisition Cost (PAC), developed by Glass Box Analytics and exclusively sold by Elsevier / Gold Standard.

Introduced earlier this year, PAC is a new drug price type that more closely tracks true acquisition cost. PAC employs predictive analytics techniques to estimate acquisition cost considering various factors, including MAC benchmarks, published price lists, existing price benchmarks, drug dispensing metrics, supply-demand measures, and survey-based acquisition costs. Independent tests show that PAC tracks drug acquisition cost with sufficient accuracy to support pricing activity.

"Glass Box Analytics has done an exceptional job developing the new price type, PAC," said Eaton Apothecary Vice President of Operating Policy John H. Lynch, III. "We are eager to begin using PAC for our company and look forward to the growth potential the new tool will offer as we integrate its intelligence into our existing systems."

Eaton Apothecary has 16 locations, including traditional retail pharmacies and those focused on home delivery and specialized care. As a classic community-centered pharmacy, Eaton Apothecary prides itself for its commendable one-on-one service with patients. With a reputation in the industry as an early-adopter of new, enhanced technologies and marketplace trends, Eaton Apothecary selected PAC, adding to the company's competitive edge.

"We are excited to be working with Eaton Apothecary as they begin to implement PAC into their systems," said Marianne Messer, Elsevier / Gold Standard President. "We have confidence that PAC meets the industry need for a drug price type that is a close indicator of true acquisition cost, and is accurate, transparent, comprehensive and timely."

Eaton Apothecary plans to utilize PAC for reimbursement analysis, wholesaler request for proposal processes with standards for deviations from the PAC price type, and as a cash pricing base.

Elsevier / Gold Standard

Based in Tampa, FL, Elsevier / Gold Standard uses innovative technologies to provide a complete suite of drug information and decision support solutions. With a tenacious commitment to product quality, Elsevier / Gold Standard solutions empower healthcare organizations, professionals and consumers to meet the most pressing healthcare challenges, improve patient safety and ensure optimal outcomes. To learn more about Elsevier / Gold Standard, visit http://www.goldstandard.com.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Tom Reller
Vice President, Global Corporate Relations, Elsevier
+1-215-239-3508
t.reller@Elsevier.com


'/>"/>
SOURCE Elsevier
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. WHEATON® Introduces a New Web Community for Scientists, Researchers, and Biopharmaceutical Packagers
2. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
3. Netsmart Selects Overland Park, Kansas, for New Office
4. Pharmaceutical Consortium Selects BioFortis Software to Manage Collaborative Clinical Data and Biobanking Activities
5. Maine Center for Creativity Selects Glenn Close and David Shaw to Receive Inaugural Maine Creative Industry Award
6. Aesthetics Pharmaceutical Company Selects 360 Vantage Closed Loop Marketing Solution for Apple iPad
7. Elsevier/Gold Standard Exclusive Publisher of New Predictive Drug Price Type
8. Data mining opens the door to predictive neuroscience
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
11. INCOM Inc. Announces Acquisition of Paradigm Optics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):